Clinical Trial

Assessment in Patients with Interstitial Lung Diseases

Study Description

Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases

The purpose of this study is to find out if combining a state-of-the-art form imaging modality with metabolomics in different types of Interstitial Lung Diseases (ILD) patients compared to controls with chronic obstructive pulmonary disorder (COPD)/emphysema and healthy controls will be a better predictor of disease progression. ILD's are a group of chronic, progressive lung diseases. The most common ILD is idiopathic pulmonary fibrosis (IPF). Metabolomics provides a "snapshot" in time of all metabolites present in a biological sample such as whole blood, plasma, serum, urine, and many other specimens. The imaging procedure should take approximately 20 minutes. All study related collections of samples will be done in a single visit if possible. There are no direct benefits to participants. This is not a treatment study.

Location

Locations Selected Location

Methods

No pharmaceutical medication involved No pharmaceutical medication involved
Patients and healthy individuals accepted Patients and healthy individuals accepted

Device - CT-V

CT-V is a newer computed tomography scan which is more comprehensive and tracks movement of the lungs.

Metabolites

Metabolites are compounds which can be measured in biospecimens and may indicate a disease or biological process.

Additional Information

Official Study Title

Integrated Radiographic and Metabolomics Risk Assessment in Patients With Interstitial Lung Diseases

Clinical Trial ID

NCT04119115

ParticipAid ID

dPNxwa